Promising combo for brain metastases falls short in early trial
Disease control
Terminated
This study tested a combination of two drugs (ASLAN001 and capecitabine) in people with HER2-positive breast cancer that had spread to the brain and was growing despite prior radiation. Only 3 participants were enrolled before the study was stopped early. The goal was to see if t…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated May 15, 2026 11:55 UTC